Induct AS (OSL:INDCT)

Induct AS Earnings Call Transcripts

Fiscal Year 2025

• Investor Update

  Significant cost reductions and a strategic focus on core healthcare solutions have positioned the company for operational cash positivity in 2025. The collaboration with AstraZeneca and Portsmouth targets rapid scaling of a high-margin asthma care pathway, with strong clinical and financial potential.

  Read full transcript →

  • Slides

Data Source: Quartr Last updated: Jan 30, 2025

Earnings call transcripts are provided by Quartr and are published within hours after each earnings call.

Update frequency:

Quarterly

Data Sources Report a data error

Stock Analysis Pro

Upgrade now for unlimited access to all data and tools.

Market Newsletter

Get a daily email with the top market news in bullet point format.